KR910700225A - 할로 치환된 아미노테트랄린 - Google Patents

할로 치환된 아미노테트랄린

Info

Publication number
KR910700225A
KR910700225A KR1019900701993A KR900701993A KR910700225A KR 910700225 A KR910700225 A KR 910700225A KR 1019900701993 A KR1019900701993 A KR 1019900701993A KR 900701993 A KR900701993 A KR 900701993A KR 910700225 A KR910700225 A KR 910700225A
Authority
KR
South Korea
Prior art keywords
halogen
bromo
methoxy
alkyl
propylamino
Prior art date
Application number
KR1019900701993A
Other languages
English (en)
Inventor
아비드 에밀 칼쓴 페르
빌헤름 윅스트롬 하칸
앤더스 아이반 스벤쓴 크젤
로니 앤더슨 베그뜨
바브로 엑크만 아그네타
피터 스트전뢰프 닐스
아네 스벤슨 닐스
Original Assignee
로버트 에이. 아미테이지
디 업존 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이. 아미테이지, 디 업존 캄파니 filed Critical 로버트 에이. 아미테이지
Publication of KR910700225A publication Critical patent/KR910700225A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

내용 없음.

Description

할로 치환된 아미노테트랄린
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 일반식(I)의 화합물 및 그의 약학적으로 허용되는 산 부가염:
    상기식에서. X1은 할로겐. CF3-OR3또는 -SR4이고: R3은 알킬(C1-C8). 알케닐(C1-C8). -CH2- 사방향족 부분. 또는 할로이클로알킬(C3-C8)또는 벤질이고; R4는 알킬(C1-C3)이고; X2는 수소, CF3또는 할로겐이고; R7은 수소 또는 메틸이고; R1은 수소, 알킬(C1-C3) 또는 사이크로프로필메틸이고; R2는 -CH2-사이크로로알킬(C3-C8), 알킬(C1-C3), -(CH2)-R5또는 -CH2CH2-Z-(CH2)CH3이고; R5는 페닐, 2-티오핀 또는 3-티오펜이고; Z는 산소 또는 황이고; p는 1 또는 2이고; q는 2 또는 3이고; r은 0 내지 3인데, 단, (1) X1이 -OR3일때, X2는 할로겐 또는 CF3이고; (2) X1이 할로겐일때, X2는 수소이고; (3) p가 2일때, X1은8-위치가 아닌 다른 위치이다.
  2. 제1항에 있어서, P가 2이고, X1및 X2가 할로겐인 화합물.
  3. 제1항에 있어서, P가 2이고, X1이 -OR3이고, X2가 할로겐인 화합물.
  4. 제1항에 있어서, P가 2이고, X2가 할로겐인 하합물.
  5. 제1항에 있어서, P가 1이고, R2가 -CH2-사이크로로알킬-(C3-C8)인 화합물.
  6. 제1항에 있어서, P가 1이고, R2가 알킬(C1-C8), -(CH2)-R5또는 -CH2CH2-Z-(CH2)CH3인 화하물.
  7. 제2항에 있어서, R2가 -CH2-사이클로알킬(C3-C8)인 화합물.
  8. 제3항에 있어서, R2가 -CH2-사이클로알킬(C3-C8)인 화합물.
  9. 제4항에 있어서, R2가 -CH2-사이클로알킬(C3-C8)인 화합물.
  10. 제1항에 있어서, 8-브로모-5-메톡시-2-(디-n-프로필아미노)테트랄린, 5-브로모-8-메톡시-2-(디-n-프로필아미노)테트랄린, 4-브로모-7-메톡시-2-(디-n-프로필아미노)인단, 시스-1S,2R-8-브로모-5-메톡시-1-메틸-2(디-n-프로필아미노)-테트랄린, 시스-1S,2R-5-브로모-8-메톡시-1-메틸-2-(디-n-프로필아미노)-테트랄린, 5-브로모-8-메톡시-2-(디-사이크로로프로필메틸아미노)테트랄린, 5-브로모-2-(n-프로필아미노)테트랄린, 7-브로모-2-(n-프로필아미노)테트랄린, 5-브로모-8-메톡시-2-(사이클로로프로필메틸아미노)테트랄린, 7-플로오로-8-메톡시-2-(디-n-프로필아미노)테트랄린 또는 (-)-5-브로모-8-메톡시-2-(디-사이클로프로필메틸아미노)테트랄린인.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019900701993A 1989-01-09 1990-01-03 할로 치환된 아미노테트랄린 KR910700225A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29516989A 1989-01-09 1989-01-09
US295169 1989-01-09
PCT/US1990/000015 WO1990007490A1 (en) 1989-01-09 1990-01-03 Halo substituted aminotetralins

Publications (1)

Publication Number Publication Date
KR910700225A true KR910700225A (ko) 1991-03-14

Family

ID=23136530

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701993A KR910700225A (ko) 1989-01-09 1990-01-03 할로 치환된 아미노테트랄린

Country Status (9)

Country Link
EP (1) EP0452390B1 (ko)
JP (1) JP2868897B2 (ko)
KR (1) KR910700225A (ko)
AT (1) ATE113271T1 (ko)
AU (1) AU4844290A (ko)
CA (1) CA2026775C (ko)
DE (1) DE69013672T2 (ko)
DK (1) DK0452390T3 (ko)
WO (1) WO1990007490A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
FR2633617B1 (fr) * 1988-07-04 1991-02-08 Adir Nouveaux derives du benzocycloheptene, leur procede de preparation et les compositions pharmaceutiques les renfermant
IL114715A (en) * 1989-02-27 1997-01-10 Lilly Co Eli Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
HUT61719A (en) * 1989-05-31 1993-03-01 Upjohn Co Process for producing 2-aminotetraline derivatives and pharmaceutical compositions comprising such compounds
SE8904127D0 (sv) * 1989-12-07 1989-12-07 Astra Ab New biocyclic amino-substituted compounds
FR2669821A1 (fr) * 1990-12-04 1992-06-05 Sanofi Sa Utilisation de phenylethanolaminotetralines pour la preparation de medicaments destines au traitement de la depression.
EP0712387B1 (en) * 1993-08-06 1999-12-08 PHARMACIA & UPJOHN COMPANY 2-aminoindans as selective dopamine d3 ligands
WO1996015099A1 (en) * 1994-11-09 1996-05-23 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
JP3878210B2 (ja) * 1995-02-01 2007-02-07 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
KR101381768B1 (ko) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1518652A1 (de) * 1965-05-29 1969-04-10 Albert Ag Chem Werke Verfahren zur Herstellung von pharmazeutisch wirksamen Derivaten des 2-Aminoindans
DE2803582A1 (de) * 1978-01-27 1979-08-02 Sandoz Ag Neue tetralinderivate, ihre herstellung und verwendung
US4192888A (en) * 1978-04-10 1980-03-11 Smithkline Corporation Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4320148A (en) * 1980-11-24 1982-03-16 Smithkline Corporation 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline

Also Published As

Publication number Publication date
ATE113271T1 (de) 1994-11-15
EP0452390A1 (en) 1991-10-23
EP0452390B1 (en) 1994-10-26
DK0452390T3 (da) 1995-04-03
CA2026775A1 (en) 1990-07-10
DE69013672T2 (de) 1995-03-30
AU4844290A (en) 1990-08-01
DE69013672D1 (de) 1994-12-01
JPH04502620A (ja) 1992-05-14
JP2868897B2 (ja) 1999-03-10
CA2026775C (en) 1998-04-07
WO1990007490A1 (en) 1990-07-12

Similar Documents

Publication Publication Date Title
KR910700225A (ko) 할로 치환된 아미노테트랄린
ATE151097T1 (de) Stabilisiertes organisches material
DK160877C (da) Fremgangsmaade til fremstilling af 2-penemforbindelser
MX9101957A (es) Carbamatos de aminosulfonilo
DK0544765T3 (da) Piperazinylderivater med affinitet for 5-HT-receptorer
PE14696A1 (es) Derivado de fenetanolamina
ES8602588A1 (es) Un procedimiento para la preparacion de nuevos antagonistas de los leucotrienos.
KR870002143A (ko) 삼환 옥스인돌 카복스아미드 유도체의 제조방법
ES2057216T3 (es) N-(1,4-benzodiazepin-3-il) amidas de acidos 1h-indol-2-carboxilicos condensados en posiciones 1,7.
ES2000706A6 (es) Procedimiento de preparacion de nuevas benzamidas y su sales
ATE129736T1 (de) Iminoalkohol-oxazolidin mischungen als feuchtigkeitsauffänger.
KR910006219A (ko) 벤즈아닐리드 유도체 및 그의 제조방법
DE69110124D1 (de) Indolderivate, herstellung und verwendung.
KR850006934A (ko) 3-페닐-2-프로펜아민 유도체의 제법
KR910016692A (ko) 신규 8-술파밀메틸렌-2-아미노 테트랄린
KR910006292A (ko) 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드
FI853685A0 (fi) Nya n-alk(en)yl-n-(o,o-disubstituerade -tiofosforyl)-n'n'-disubstituerade glycinamider, foerfarande foer framstaellning av dessa samt kvalstergifter, insektgifter och svampgifter vilka innehaoller dessa som aktiv bestaondsdel.
PE20010125A1 (es) Compuestos derivados de piperazinil-pirazina que se unen al receptor 5-ht 2c
ATE3030T1 (de) N,n'-dialkylaminoalkylethylendiamine und verfahren zu deren herstellung.
PT92494A (pt) Processo para a preparacao de novos derivados do indol
KR970006283A (ko) 신규 아민고리 화합물
BE905297A (fr) Derives heterocycliques.
KR910019976A (ko) N-아릴테트라히드로프탈이미드
KR830003458A (ko) 2-티옥소-3-벤조치아졸린 아세토니트릴의 유도체
ATE108444T1 (de) 3-isoxazolonderivate, ihre herstellung und ihre anwendung in der therapeutik.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application